Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Vivos Therapeutics (VVOS) Leases (2021 - 2025)

Vivos Therapeutics' Leases history spans 5 years, with the latest figure at $4.2 million for Q4 2025.

  • Quarterly results put Leases at $4.2 million for Q4 2025, up 303.68% from a year ago — trailing twelve months through Dec 2025 was $4.2 million (up 303.68% YoY), and the annual figure for FY2025 was $4.2 million, up 303.68%.
  • Leases for Q4 2025 was $4.2 million at Vivos Therapeutics, up from $3.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $4.2 million in Q4 2025 to a low of $516000.0 in Q4 2021.
  • The 5-year median for Leases is $1.5 million (2023), against an average of $1.7 million.
  • The sharpest move saw Leases plummeted 31.11% in 2023, then soared 303.68% in 2025.
  • Year by year, Leases stood at $516000.0 in 2021, then surged by 228.49% to $1.7 million in 2022, then fell by 18.29% to $1.4 million in 2023, then decreased by 25.49% to $1.0 million in 2024, then soared by 303.68% to $4.2 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $4.2 million, $3.4 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.